How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Ryan Eichler holds a B.S.B.A with a concentration in Finance from Boston University. He has held positions in, and has deep experience with, expense auditing, personal finance, real estate, as well as ...

Should developing economies follow the United States and China by building national champions? DOUGLAS IRWIN is the John French Professor of Economics at Dartmouth College and a nonresident senior ...

Waiting for your refund is a test of patience, especially if you're using the money to pay rent, credit card bills or other necessities, as nearly 70% of filers say they will, according to a recent ...

To own Recursion, you have to believe its AI driven platform can turn early clinical assets and pharma collaborations into durable, less partnership dependent revenue, while managing heavy cash burn.